540 results about "Lactobacillus reuteri" patented technology

The invention relates to a preparation method of a biological preservative. As known to all, along with the rapid development of the society, chemical preservatives have been used in food, have strong impact on food safety and endanger the health of consumers, therefore, the use of preservatives causes great concern of government departments and consumers. According to the biological preservative, natural plants and microbial antibiotic substances are used as base materials, for example, the biological preservative is prepared by mixture of carboxymethyl chitosan, xylooligosaccharide, nisin from lactic streptococci, acetic acid, lactobacillus reuteri, pediococcus acidilactici, calcium citrate, ionized calcium, lactic acid, plant essential oil and water. The biological preservative can inhibit growth of harmful microorganisms by antagonistic and competitive inhibition effects among different microorganisms and produce extracted and separated components of antibacterial active ingredients having antifungal and antibacterial functions in normal growth and metabolism processes, thereby achieving antiseptic and fresh-keeping effects.

The invention relates to the technical field of microorganism, and discloses a Lactobacillus reuteri and its application. The preservation number of the Lactobacillus reuteri CCFM8631 is CGMCC No.14394; the level of mice peripheral neurotransmitter 5-hydroxytryptamine can be significantlyimproved; the rise of the mice peripheral blood testonsterone level and the abundant abnormity of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora by high glucose and high fatty diets are recovered; the tolerated simulative gastrointestinal fluid is rapidly planted in an intestinal tract, so as to significantly improve the pathological injury of metabolic syndrome mice liver and duodenum and rise of triglyceride and total cholesterol content in the serum by high glucose and high fatty diets are significantly improved; the Lactobacillus reuteri can be used for preventing, delaying or treating metabolic disorder such as metabolic syndrome, irritable bowel syndrome, and anxiety, depression and other metal diseases related to irritable bowel syndrome.

Strains of Lactobacillus that have been selected for their capability of reducing the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with good binding to the oral mucins and dental plaque, Administering the strains in a product such as food, reduces and treats dental caries. Preferred strains are Lactobacillus reuteri strain ATTC PTA-4965 or Lactobacillus reuteri strain ATTC PTA-4964.

Cryptosporidium parvum (the cause of cryptosporidiosis) has become one of the most common enteropathogens causing diarrhea worldwide. Symptoms associated with cryptosporidiosis are very debilitating especially in the immunocompromised subject (e.g., AIDS patient). Clinical features include severe, chronic diarrhea, abdominal cramps, fatigue, weight loss, etc. which lead to increased health care costs and increased mortality. There is disclosed herein a method of inhibiting the severity of Cryptosporidium parvum infection by enterally administering a therapeutically effective amount of Lactobacillus reuteri.

The invention discloses two lactobacillus separation strains with anti-inflammatory activity and beneficial properties, which are Lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89. The two lactobacillus separation strains are respectively preserved in the Bioresouce Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) by preservation numbers of BCRC 910355 and BCRC 910340 and preserved in the China Center for Type Culture Collection (CCTCC) by the preservation numbers of CCTCC M 207153 and CCTCC M 207154. The two lactobacillus separation strains and subculture offspring thereof can be used for preparing various food products and pharmaceutical composition for curing and/or mitigating diseases (such as rheumatoid arthritis) relevant to inflammation.

The invention discloses two Lactobacillus isolated strains with anti-inflammatory activity and beneficial probiotic characteristics, namely lactobacillus sakei GMNL-76 and Lactobacillus reuteri GMNL-89, which are respectively preserved at the Bioresource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) with the preservation numbers of BCRC 910355 and BCRC 910340, and preserved at the China Center for Type Culture Collection (CCTCC) with the preservation numbers of CCTCC M 207153 and CCTCC M 207154. The two Lactobacillus isolated strains and subculture progeny thereof can be used for preparing various food products, and drug composites used for curing and/or relieving diseases related to inflammation, such as rheumatoid arthritis.

Present invention features a novel use of Lactobacillus for treating type 2 diabetes, wherein the Lactobacillus is Lactobacillus reuteri GMNL-89 with the deposition numbers of BCRC 910340 and CCTCC M 207154 and comprises of live, dead bacteria or supernatant of the bacterial culture(s) and a pharmaceutically acceptable vehicle. The invention also discloses the efficacies of the indicated Lactobacillus strain including anti-oxidative enzyme activity, anti-inflammation, reduction of blood glucose level, reduction of triglycerides, reduction of total cholesterol, reduction of LDL, increase of HDL and improve insulin utilization.

The invention relates to lactobacillus reuteri and application thereof. Lactobacillus reuteri is lactobacillus reuteri LZ262 which is preserved in the Common Microorganism Center of the China Committee for Culture Collection of Microorganisms on 13 August, 2015 with the preservation number of CGMCCNo.11240. Lactobacillus reuteri LZ262 is from the intestinal tract of a healthy pig, can be colonized in a human body and an animal body, and has higher tolerance to gastric acid and bile salt; in addition, lactobacillus reuteri LZ262 has a better suppression effect on Escherichia coli, and has a higher survival rate after spray-drying, and higher fermentation density is achieved by improving a fermentation formula; the strain has a better effect of synergistic growth with other types of lactic acid bacteria, can be used for food and animal feed additives, and can also be widely applied to other food and biological products.

The invention discloses a lactobacillus reuteri strain and application thereof. The lactobacillus reuteri strain is lactobacillus reuteri RI021 preserved in China General Microbiological Culture Collection Center on March 11, 2011, and the accession serial number in the collection center is CGMCC (China General Microbiological Culture Collection Center) No. 4650. The lactobacillus reuteri strain and a lactobacillus reuteri preparation thereof are mainly used as feed additives for animals and can be used for regulating the microeubiosis in animal intestines, thus achieving the effect of enhancing the non-specific immune function so as to prevent diseases, simultaneously providing nutritional factors, promoting the digestion and absorption of nutrients, promoting the growth of the animals and improving the feed conversion rate.

The invention discloses a probiotic and prebiotic composition for forming lean body mass and application thereof, and relates to the field of biomedicine. The composition comprises probiotics such asbifidobacterium lactis, bifidobacterium longum, lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus acidophilus, streptococcus thermophilus, bacillus coagulans and clostridium butyricum, anda prebiotic mixture is also added. By reasonably matching the components of the composition, the intestinal flora is effectively regulated, and the obesity is more efficiently and healthily relieved;for people with normal weight, the weight reduction effect is not obvious, but the body shape is more beautiful; meanwhile, the composition can effectively prevent hyperglycemia, hyperlipidemia and other diseases and improve the body immunity, is suitable for a wider range of people, and can be applied to food, pharmacy and healthy or natural product production.

The invention discloses novel lactobacilli and a composition thereof, and an application thereof in preparing medicines used for ameliorating diabetes and complications thereof. The composition comprises an effective amount of at least one lactobacillus selected from: lactobacillus reuteri GMNL-89, lactobacillus gasseri GMNL-205, and lactobacillus reuteri GMNL-263; and a pharmaceutically acceptable carrier. The lactobacillus gasseri GMNL-205 and the lactobacillus reuteri GMNL-263 are novel lactobacilli. The composition and novel lactobacilli provided by the invention have novel applications for ameliorating diabetes and complications thereof.

The present invention relates to four kinds of lactobacilli, including Lactobacillus gasseri with preservation number of CGMCC No. 0840, Lactobacillus reuteri with preservation number of CGMCC No. 0841, Lactobacillus acidophilus with preservation number of CGMCC No. 0842 and Lactobacillus fermentum with preservation number of CGMCC No. 0843, separated from piglet intestinal tract and bred. The combination of the four kinds of lactobacilli is used in preparing the probiotics preparation for preventing and treating piglet ablactation diarrhoea and promoting growth, and the probiotic preparation is added into feed for ablactated piglet to prevent and treating diarrhoea and promote its growth.

A method for treating or preventing a Human Immunodeficiency Virus (HIV) infection, or treating or preventing Acquired Human Immunodeficiency Syndrome (AIDS), in a subject in need thereof, is disclosed. The method involves colonizing a genetically modified probiotic Lactobacillus reuteri RC-14 in the gastrointestinal tract of a subject, wherein the probiotic is able to secrete two or more fusion inhibitors that decrease or prevent HIV production and CD4+T cell depletion in the gastrointestinal tract.

The invention discloses novel lactacidophilus, a composition thereof and use thereof in preparation of medicines for relieving diabetes mellitus and diabetic complications. The composition comprises at least one lactacidophilus which may be lactobacillus reuteri CMNL-89, lactobacillus gasseri GMNL-205 and lactobacillusreuteri CMNL-263. The lactobacillus gasseri GMNL-205 and the lactobacillusreuteri CMNL-263 are novel lactacidophilus. The composition or novel lactacidophilus can be used for relieving symptoms of diabetes mellitus and diabetic complications.

The invention discloses a probiotic composition for relieving anxiety or depression and an application thereof. The probiotic composition comprises prebiotics, a K-KLJ probiotic combination and functional substances. The K-KLJ probiotic composition contains at least one of lactobacillus plantarum, lactobacillus reuteri, lactobacillus casei, and lactobacillus helveticus, or also contains at least one of lactobacillus rhamnosus, lactobacillus acidophilus, bifidobacterium animalis and bifidobacterium longum. The probiotic composition of the present invention can significantly increase quantity ofbeneficial intestinal flora, improve intestinal discomfort, and reduce chronic inflammation, thereby reducing unhealthy emotion, and preventing emotional diseases such as depression and anxiety. Moreover, according to the invention, the combination of probiotic strains, the prebiotics, the probiotic strains and the functional substances have effect of significant synergistic enhancement.

The present invention provides lactobacillus reuteri for preventing ulcerative colitis. The strain is named as lactobacillus reuteri RAM0101 and deposited on May 27, 2019 at China General Microbiological Culture Collection Center and has a preservation number of CGMCC NO.17853. C57BL/6N mice are used as test objects, dextran sodium sulfate (DSS) is used to induce the mice to form an ulcerative colitis model and the model is also used to investigate effectiveness of the strain in preventing the ulcerative colitis. The lactobacillus reuteri can relieve weight loss, diarrhea, hematochezia and disease activity index (DAI) score of the ulcerative colitis mice induced by the DSS, protects pathological damages of colon tissues of the mice induced by the DSS, can enhance colon tissue epithelial barrier completeness and is also free of toxin and harms.

The invention discloses fruit and vegetable ferment freeze-dried powder and a preparation method thereof. The fruit and vegetable ferment freeze-dried powder has good health-care effects on intestines and stomachs. The preparation method of the fruit and vegetable ferment freeze-dried powder comprises the following steps of (1) preparing raw materials of the fruit and vegetable ferment freeze-dried powder; (2) after treatment of the raw materials, firstly, adding lactobacillus reuteri for fermentation, and performing anaerobic fermentation under the condition of 35-37 DEG C for 2-3 days, then lowering the temperature to 30-35 DEG C, adding saccharomyces cerevisiae for fermentation under the condition that the pH is 3.5-5.5 for 2-3 days, enabling filtered sterile air to be led, and finally, adding bifidobacterium longum for anaerobic fermentation for 2-3 days so as to obtain fermentation broth; and (3) filtering the fermentation broth, and performing vacuum freeze drying so as to obtain the fruit and vegetable ferment freeze-dried powder. According to the fruit and vegetable ferment freeze-dried powder and the preparation method thereof disclosed by the invention, various green pollution-free fruits, vegetables, yams, beans and wild herbs, having good health-care effects on intestines and stomachs are selected to be used as fermentation base materials, and through multistage fermentation and post-treatment, the fruit and vegetable ferment freeze-dried powder is obtained.

The invention discloses a micro-ecological composition for improving constipation by targeting intestinal flora and a preparation of the micro-ecological composition. The micro-ecological compositioncomprises probiotics, prebiotics and medicinal and edible traditional Chinese medicines, wherein the probiotics are selected from at least one of bifidobacterium animalis, bifidobacterium adolescentis, bifidobacterium longum, bifidobacterium breve, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus helveticus, lactobacillus plantarum, lactobacillus reuteri, lactobacillus paracasei and bacillus coagulans; the prebiotics are selected from at least one of stachyose, fructo-oligosaccharide, isomalto-oligosaccharide, galacto-oligosaccharide, inulin, resistant dextrin and xylooligosaccharide; and the medicinal and edible traditional Chinese medicines are selected from at least one of semen sesami nigri, semen cassiae, fructus cannabis, honey, semen lablab album, semen coicis, poria cocos and lotus leaves. The micro-ecological composition can effectively regulate intestinal tract micro-ecology in a targeted mode, and finally the purpose of improving constipation is achieved.

The invention discloses a complex probiotics solid drink. The product is prepared from 0.04g of anti-allergy complex bacterial powder, 1.76g of inulin and 0.2g of stachyose; each bag of the product contains 6 billion of bacterial powder, the complex bacterial powder includes lactobacillus reuteri, lactobacillus paracasei, bifidobacterium longum and bifidobacterium lactis, and the 6 billion of bacterial powder includes 1 billion of lactobacillus reuteri, 3 billion of lactobacillus paracasei, 1.5 billion of bifidobacterium longum and 0.5 billion bifidobacterium lactis. The complex probiotics solid drink has the beneficial effects of being suitable for any people, regulating immunologic balance, relieving allergy, giving consideration to both regulation of intestinal flora and relieving of diarrhea and constipation.

The invention relates to Lactobacillus reuteri DSM 17938 for promoting the establishment of healthy and normal cognitive function in young mammals. In particular, the invention relates to the use of Lactobacillus reuteri DSM 17938 for promoting development of the brain structures responsible for cognitive functions (e.g. cortex and hippocampus) and its associated neural pathways and/or to reverse retardation and/or to prevent retardation of the establishment of cognitive functions. Humans or animals and, in particular, a foetus, pre-term or term born infant, toddler or child or a young adult may benefit from the invention.

The invention discloses an application of breast milk-derived lactobacillus reuteri in reducing fat and regulating fat metabolism rhythm, and belongs to the fields of microbial technology and food science. The lactobacillus reuteri FN041 can prevent and/or treat lipid metabolism rhythm disorder and has the functions particularly embodied in: (1) significantly reducing weight gain under the influence of high fat; (2) significantly reducing abnormal increase of peritesticular adipose tissue indexes under the influence of high fat; (3) significantly reducing hepatic fatty infiltration and abnormal increase of testicular fat cell area under the influence of high fat; (4) significantly decreasing abnormal increase of the content of TG, TC, LDL-C and HDL-C in serum under the influence of high fat; (5) significantly decreasing abnormal increase of the plasma FD4 content and the content of LPS, LBP and TNF-alpha in serum under the influence of high fat; and (6) restoring the content of triglyceride in serum and the rhythm of the expression of living clock genes Clock, Bmal1 and Per2 in liver under the influence of high fat.

Methods for the controlled activation of the reuterin-production machinery of Lactobacillus reuteri by adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts of L. reuteri that are loaded with reuterin, and the use of such loaded bacteria for applications such as prevention and treatment of diseases, for food applications and the like.

The invention relates to a milk peptide polynary probiotic solid beverage, and belongs to the field of foods. The milk peptide polynary probiotic solid beverage is made from the following components with content in percentage: composite strains including 14%-23% of lactobacillus rhamnosus, 0.1%-0.8% of bifidobacterium lactis, 0.2%-0.9% of animal bifidobacterium lactis and 0.1%-0.7% of lactobacillus reuteri, 0.2%-1% of added fructo-oligosaccharide, 0.2%-1% of added isomaltooligosacharide, 0.1%-0.8% of added stachyose, 0.3%-1.0% of egg white protein polypeptide powder and 0.3%-1.0% of whey protein peptide. The product namely the milk peptide polynary probiotic solid beverage provided by the invention is rich in dietary fibers and prebiotics, balanced in nutrients, low in storage and transportation requirements and long in quality guarantee period.